Startseite Crystal structure of (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-hydroxybut-2-en-1-one C9H12N2O2
Artikel Open Access

Crystal structure of (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-hydroxybut-2-en-1-one C9H12N2O2

  • Smaail Radi EMAIL logo , Said Tighadouini , Taibi Ben Hadda , Mehmet Akkurt , Namık Özdemir , Muhammad Sirajuddin und Yahia N. Mabkhot
Veröffentlicht/Copyright: 23. März 2016

Abstract

C9H12N2O2, triclinic, P1̅ (no. 2), a = 6.6954(7) Å, b = 7.6325(8) Å, c = 9.8928(11) Å, α = 95.908(9)°, β = 92.810(9)°, γ = 108.360(8)°. V = 475.49(9) Å3, Z = 2, Rgt(F) = 0.0606, wRref(F2) = 0.1549, T = 296(2) K.

CCDC no.:: 979896

The figure shows the asymmetric unit of the title structure. Tables 13 contain details of the methods used and a list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal:Colourless, plate, size 0.040×0.317×0.540 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:0.91 cm−1
Diffractometer, scan mode:STOE IPDS 2, ω scans
2θmax:57.92°
N(hkl)measured, N(hkl)unique:9019, 2509
N(param)refined:122
Programs:X-Area [9], SHELX [10]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomSitexyzUiso
H(1)2i0.23410.3611−0.03940.118
H(1A)2i−0.29240.2720−0.03140.124
H(1B)2i−0.30910.10330.05030.124
H(1C)2i−0.25980.0912−0.10300.124
H(3)2i−0.01470.17830.21250.072
H(6)2i0.71370.37810.31400.073
H(8A)2i0.79510.38560.667400.124
H(8B)2i0.91250.32450.54720.124
H(8C)2i0.76070.17400.62440.124
H(9A)2i0.33810.26240.71430.124
H(9B)2i0.39130.07730.68240.124
H(9C)2i0.16960.08700.63230.124
Table 3:

Fractional coordinates and atomic displacement parameters (Å2).

AtomSitexyzU11U22U33U12U13U23
O(1)2i0.1092(2)0.3321(2)−0.0671(1)0.0770(9)0.107(1)0.0560(8)0.0321(9)0.0070(7)0.0188(8)
O(2)2i0.4218(2)0.3925(2)0.1072(1)0.0608(8)0.104(1)0.0670(8)0.0196(7)0.0154(6)0.0352(8)
N(1)2i0.2620(2)0.2152(2)0.4169(2)0.0632(9)0.062(1)0.0519(8)0.0202(7)0.0068(7)0.0125(7)
N(2)2i0.3994(3)0.2154(2)0.5212(2)0.075(1)0.0603(9)0.0505(8)0.0259(8)0.0061(7)0.0105(7)
C(1)2i−0.2376(3)0.1722(4)−0.0188(2)0.067(1)0.101(2)0.078(1)0.027(1)−0.008(1)0.001(1)
C(2)2i−0.0075(3)0.2498(3)0.0239(2)0.067(1)0.065(1)0.059(1)0.0266(9)0.0081(9)0.0044(9)
C(3)2i0.0754(3)0.2360(3)0.1501(2)0.057(1)0.067(1)0.058(1)0.0182(8)0.0123(8)0.0139(8)
C(4)2i0.2944(3)0.3072(2)0.1873(2)0.061(1)0.057(1)0.0525(9)0.0234(8)0.0118(8)0.0117(8)
C(5)2i0.3857(3)0.2848(2)0.3202(2)0.0573(9)0.051(1)0.0533(9)0.0199(7)0.0103(7)0.0093(7)
C(6)2i0.5988(3)0.3282(3)0.3632(2)0.059(1)0.065(1)0.062(1)0.0230(9)0.0089(8)0.0101(9)
C(7)2i0.6036(3)0.2820(3)0.4932(2)0.065(1)0.058(1)0.063(1)0.0272(9)−0.0002(8)0.0027(8)
C(8)2i0.7841(4)0.2925(4)0.5918(2)0.084(1)0.093(2)0.076(1)0.038(1)−0.012(1)0.005(1)
C(9)2i0.3176(4)0.1554(4)0.6484(2)0.103(2)0.095(2)0.056(1)0.035(1)0.012(1)0.022(1)

Source of material

A solution of ethyl 1,5-dimethyl-1H-pyrazole-3-carboxylate (12 mmol) in THF (25 mL) was added to a suspension of sodium (22 mmol) in THF (50 mL), and then acetone (1.2 g; 20.6 mmol) was added at 273 K. The resulting mixture was stirred at 273 K for 48 h and the formed residue was filtered, washed with THF, and neutralized with acetic acid to pH 5 after being dissolved in water. The organic layer was extracted with CH2Cl2, dried and concentrated in vacuum. The resulting mixture was chromatographed on silica using CH2Cl2 as eluant to give the target product. Crystals suitable for X-ray diffraction analysis were obtained by slow evaporated of methanol from the mixture; yield: 37%; M.p. 356–357 K.

Experimental details

The hydroxyl H atom and H atoms bonded to C atoms were positioned geometrically and were refined using a riding model with Uiso(H) = 1.5Ueq(O) for hydroxyl and Uiso(H) = 1.2Ueq(C) for the others.

Discussion

A new generation of highly promising inhibitors bearing β-keto-enol functionality has emerged. Their versatile utility in medicinal chemistry is firmly established including anti-HIV [1, 2], antitumor [35], anti-influenza [6], antioxidant [7], and anti-inflammatory [8] activities. In this study we coupled ethyl pyrazole carboxylate with acetone to produce the title compound in acceptable yield.

The crystal structure is quite interesting and displays the formation of an intramolecular OH—O hydrogen bond (see the figure). The structure leads to two independent N1, O2 and O1, O2-bidentate units having two different geometries with a very attractive evidence for even semi-combination probably existing between them, leading to a bis-bidentate N1, O2, O1-unit. However, both are held together by means of intra-electrostatic forces and van der Waals interactions. The oxygen atoms O1, O2 are separated by a distance of 2.538 Å. This distance is always found in the case of antibacterial pharmacophore site. Hence, this compound constitutes a promising anti-HIV agent. The whole molecule is almost planar, with an rms deviation of 0.002 Å for all non-hydrogen atoms. In the crystal, π−π stacking interactions [centroid-centroid distance = 3.5901(12) Å] between the pyrazole rings stabilize the molecular packing.


Corresponding author: Smaail Radi, Department of Chemistry, Faculty of Sciences, Mohamed Premier University, Oujda 60000, Morocco, e-mail:

Acknowledgements:

The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for its funding this Prolific Research group (PRG-1437-29).

References

1. Pommier, Y.; Johnson, A. A.; Marchand, C.: Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 4 (2005) 236–248.10.1038/nrd1660Suche in Google Scholar PubMed

2. Egbertson, S. S.; Anthony, N. J.; Summa, V.: From diketo acids to heterocyclic templates: history of HIV integrase medicinal chemistry at Merck West Point and Merck Rome (IRBM) leading to discovery of raltegravir. In: Pharmaceutical & Medicinal Chemistry (Ed. Neamati, N.), pp 197–230, Wiley, 2011.10.1002/9781118015377.ch14Suche in Google Scholar

3. Goldgur, Y.; Craigir, R.; Cohen, G. H.; Fujiwara, T.; Yoshinaga, T.; Fujishita, T.; Sugimoto, H.; Endo, T.; Murai, H.; Davies, D. R.: Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Proc. Natl. Acad. Sci. USA, 96 (1999) 13040–13043.10.1073/pnas.96.23.13040Suche in Google Scholar PubMed PubMed Central

4. Tan, K. L.; Ali, A.; Du, Y.; Fu, H.; Jin, H. X.; Chin, T. M.; Khan, M.; Go, M. L.: Synthesis and evaluation of bisbenzylidenedioxotetrahydro-thiopranones as activators of endoplasmic reticulum (ER) stress signaling pathways and apoptotic cell death in acute promyelocytic leukemic cells. J. Med. Chem. 57 (2014) 5904–5918.10.1021/jm401352aSuche in Google Scholar PubMed PubMed Central

5. Liang, G.; Shao, L.; Wang, Y.; Zhao, C.; Chu, Y.; Xiao, J.; Zhao, Y.; Li, X.; Yang, S.: Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg. Med. Chem. 17 (2009) 2623–2631.10.1016/j.bmc.2008.10.044Suche in Google Scholar PubMed

6. Ishikawa, Y.; Fujii, S.: Binding mode prediction and inhibitor design of anti-influenza virus diketo acids targeting metalloenzyme RNA polymerase by molecular docking. Bioinformation 6 (2011) 221–225.10.6026/97320630006221Suche in Google Scholar PubMed PubMed Central

7. Anand, P.; Thomas, S. G.; Kunnumakkara, A. B.; Sundaram, C.; Harikumar, K. B.; Sung, B.; Tharakan, S. T.; Misra, K.; Priyadarsini, I. K.; Rajasekharan, K. N.; Aggarwal, B. B.: Biological activities of curcumin and its analogues (congeners) made by man and mother nature. Biochem. Pharmacol. 76 (2008) 1590–1611.10.1016/j.bcp.2008.08.008Suche in Google Scholar PubMed

8. Liang, G.; Li, X.; Chen, L.; Yang, S.; Wu, X.; Studer, E.; Gurley, E.; Hylemon, P. B.; Ye, F.; Li, Y.; Zhou, H.: Synthesis and anti-inflammatory activities of monocarbonyl analogues of curcumin. Bioorg. Med. Chem. Lett. 18 (2008) 1525–1529.10.1016/j.bmcl.2007.12.068Suche in Google Scholar PubMed PubMed Central

9. Stoe & Cie: X-Area & X-RED32 Software; Stoe & Cie GmbH: Darmstadt, Germany, 2002.Suche in Google Scholar

10. Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Suche in Google Scholar PubMed

Received: 2016-2-10
Accepted: 2016-3-6
Published Online: 2016-3-23
Published in Print: 2016-6-1

©2016 Smaail Radi et al., published by De Gruyter.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Artikel in diesem Heft

  1. Cover and Frontmatter
  2. Crystal structure of fac-hexacarbonylbisμ2-(3-carboxy-3′-carboxylato-2,2′-bipyridine)-κ3N,N′:O-dirhenium(I) tetrahydrate, C30H22N4O18Re2
  3. The crystal structure of bis(4-(2,4-dimethylphenyl)piperazin-1-yl)methane, C25H36N4
  4. Crystal structure of bis(triphenylphosphine-κP)bis(μ2-1H,1′H-2,2′-biimidazole-κ3N,N′:N′)disilver(I) bis(tetrafluoroborate), C48H42Ag2B2F8N8P2
  5. The crystal structure of 1,2-bis(2-pyrazinecarboxamido)-benzene, C16H12N6O2
  6. Redetermination of the crystal structure of 3-bromobenzoic acid, C7H5BrO2
  7. Crystal structure of bis(ethyltriphenylphos-phonium) tetrabromidocuprate(II), (C20H20P)2[CuBr4]
  8. Crystal structure of 2-(4-bromophenyl)-1,3-dimethyl-2,3-dihydro-1H-perimidine, C19H17BrN2
  9. Crystal structure of trans-diaqua-bis(3-(pyrazin-2-yl)-5-(pyridin-4-yl)1,2,4-triazol-1-ido-κ2N,N′)-cobalt(II),C22H18CoN12O2
  10. Crystal structure of hexaaquamanganese(II) bis((E)-4-((4-(dimethylamino)phenyl)diazenyl)benzenesulfonate), C28H40MnN6O12S2
  11. Crystal structure of butyl 2-(3,5-dimethyl-1,1-dioxido-2H-1,2,6-thiadiazin-4-yl)benzoate, C16H20N2O4S
  12. Crystal structure of hexaaquabis(μ2-3-(6-carboxylatopyridin-2-yl)-5-(pyrazin-2-yl)-1,2,4-triazol-1-ido)bis(μ3-3-(6-carboxylatopyridin-2-yl)-5-(pyrazin-2-yl)-1,2,4-triazol-1-ido)tetra-manganese(II) dihydrate, C48H40Mn4N24O16
  13. Crystal structure of catena-poly[diaqua-bis(μ2-1,3-di(pyridin-4-yl)propane-κ2N:N′)cadmate(II)] bis(2-aminoisonicotinate) tetrahydrate, C38H50CdN8O10
  14. Crystal structure of succinic acid — 4-((pyridin-4-ylmethyl)sulfanylpyridine (1/1), C15H16N2O4S
  15. Crystal structure of tetrakis(μ2-acetato-κ2O:O′)bis(2-((pyridin-4-ylmethyl)sulfanyl)pyridine-κN)dicopper(II), C30H32N4O8S2Cu2
  16. Crystal structure of 1-((2R,3S)-2,3-dimethyl-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)-2-phenoxyethan-1-one, C18H19NO3
  17. Crystal structure of tetramethylammonium sulfanilate, C10H18N2O3S
  18. Crystal structure of triethylammonium 2′-carboxy-[1,1′-biphenyl]-2-carboxylate, C20H25NO4
  19. Crystal structure of 2-(4-acetyl-2,6-dimethylphenyl)-5,6-dichloro-1H-isoindole-1,3(2H)-dione, C18H13Cl2NO3
  20. Crystal structure of diaqua-bis(μ3-2-methyl-6-oxidopyridinium-4-carboxylato-κ3O:O′:O′′)neodymium(III) chloride, C14H16ClN2O8Nd
  21. Crystal structure of 5-methoxy-4-methyl-2-(2-methylbenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one, C12H15N3O2
  22. The crystal structure of 1-(4-(2-chloroethoxy)phenyl)ethanone
  23. Crystal structure of (E)-4-(2-(4-(diethylamino)phenyl)diazen-1-ium-1-yl)benzenesulfonate monohydrate
  24. Crystal structure of 2,2′-[(1E)-prop-1-ene-1,2-diyldisulfanediyl]bis(5-methyl-2,5-dihydro-1,3,4-thiadiazole, C9H10N4S4
  25. Crystal structure of poly [μ2-acetato-κ3-O,O′:O′)diaqua(μ3-isophthalato-κ4O,O′:O′′:O′′′)cerium(III)] monohydrate (C10H13O9Ce)
  26. Crystal structure of tris((2-(2,2-dicyanovinyl)phenoxy)ethyl)amine, C36H27N7O3
  27. Crystal structure of catena[diaqua-bis(μ2-1,3-bis((1H-tetrazol-1-yl)methyl)benzene-κ2N:N′)copper(II)] dinitrate, C20H24CuN18O8
  28. Crystal structure of (4-(1H-imidazol-5-yl)benzoic acid-κN) (4-(1H-imidazol-5-yl)benzoato-κN)silver(I), C20H15N4O4Ag
  29. Crystal structure of 2-amino-3-cyano-7,7-dimethyl-5-oxo-4-(3,4,5-trifluorophenyl)-4H-5,6,7,8-tetrahydrobenzo[b]pyran, C18H15F3N2O2
  30. Crystal structure of (2-(2-chlorophenyl)-5-ethyl-1,3-dioxan-5-yl)methanol hemihydrate, C13H17ClO3 · 0.5 H2O
  31. Crystal structure of catena-poly[diaqua-bis(benzene-1,2,4,5-tetracarboxylato-κN)(m2-2-(1H-1,2,4-trizol-1-ylmethyl)-1H-3,1-benzimidazol-3-ium-κ2O:O′)zinc(II)] dihydrate, C30H30N10O12Zn
  32. Crystal structure of [2,2′-((((ethane-1,2-diylbis(oxy-κ2O,O′))bis(2,1-phenylene))bis(azanylylidene-κ2N,N′))bis(methanylylidene))diphenolato-κ2O′′,O′′′]zinc(II), C28H22N2O4Zn
  33. Crystal structure of (E)-1-(3,4-dimethoxyphenyl)-3-(dimethylamino)prop-2-en-1-one, C13H17NO3
  34. Crystal structure of bis(2-fluoro-4-nitrophenyl) terephthalate C20H10F2N2O8
  35. Crystal structure of catena-[aqua((4-carboxyphenyl)acetato-κO)(μ2-(4-carboxyphenyl)acetato-κ2O:O′)bis(4,4′-ethene-1,2-diyldipyridine-κN)manganese(II)], C42H36N4O9Mn
  36. Crystal structure of N′-(2-hydroxybenzylidene)-3,4-dimethyl-1H-pyrrole-2-carbohydrazide, C14H15N3O2
  37. Crystal structure of bis(8-ethyl-5-oxo-2-(piperazin-4-ium-1-yl)-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylato-κ2O,O′)copper(II) benzene-1,4-dicarboxylate dihydrate, C36H42CuN10O12
  38. Crystal structure of diaquabis(μ2-biphenyl-2,2′-dicarboxylato-κ2O:O′)bis(1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylato)zinc(II), C60H56N6Zn2O16F2
  39. Crystal structure of 2-amino-4-(4-fluorophenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C16H13FN2O2
  40. The crystal structure of hexaqua(μ2-3-(3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl)propanoato-1κ2O,O′;2κO′)(3-(3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl)propanoato-κO)(3-(3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl)propanoato-κ2O,O′)digadolinium(III) octahydrate, C60H76Gd2N18O32
  41. Crystal structure of hexacarbonyl bis(μ2-2-methoxybenzenethiolato-κ2S)pyridine(triphenylphosphane)dirhenium(I), C43H34NO8PS2Re2
  42. Crystal structure of 14-((1-(benzyloxycarbonyl-amino)-2-methylpropan-2-yl)sulfanyl)acetate Mutilin, C34H49NO6S
  43. Crystal structure of 2-methoxy-6-(((2-(1-methyl-1H-benzo[d] imidazol-2-yl)phenyl)imino)methyl)phenol — ethanol (1/1), C24H25N3O3
  44. Crystal structure of 2-(bis(methylthio)methylene)-1-phenylbutane-1,3-dione, C13H14O2S2
  45. Crystal structure of (E)-2-(bis(methylthio)methylene)-1-phenyl-3-(2-phenylhydrazono)butan-1-one, C19H20N2OS2
  46. Crystal structure of dichlorido(2-(1-methyl-1H-benzo[d]imidazol-2-yl)aniline-κ2N,N′)zinc(II)
  47. Crystal structure of bis(1-methyl-1H-tetrazole-5-thiolato)mercury(II)
  48. Crystal structure of (E)-2-styryl-1-ferrocenylsulfonyl-1H-imidazo[4,5-b]pyridine, C24H19FeN3O2S
  49. Crystal structure of aquabis(1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-4-ium-1-yl)-1,4-dihydroquinoline-3-carboxylato-κ2O,O′)copper(II) thiophene-2,5-dicarboxylate trihydrate, [Cu(C17H18N3FO3)2(H2O)](C6H2SO4)·3(H2O)
  50. Crystal structure of 2-amino-4-(2,6-dichlorophenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C18H16Cl2N2O2
  51. Crystal structure of 2,4,6,8,10,12-hexanitro-2,4,6,8,10,12-hexaazatetracyclo[5·5·0·05·9·03·11]dodecane 1/3 hydrate, C6H8N12O13
  52. Crystal structure of monocarbonyl(N-nitroso-N-oxido-phenylamine-κ2O,O′)(triphenylarsine-κAs)rhodium(I), C25H20AsN2O3Rh
  53. The crystal structure of 1-(4-(4-chlorophenoxy)-2-chlorophenyl)ethanone, C14H10Cl2O2
  54. Crystal structure of N,N-diethyl-2-(2-(6-(4-methoxybenzyl)-7-oxo-7H-thiazolo[3,3-b][1,2,4]triazin-3-yl)phenoxy)acetamide, C25H26N4O4S
  55. Crystal structure of tetraqua((E)-4,4′-(diazene-1,2-diyl)bis(5-oxo-4,5-dihydro-1,2,4-triazol-1-ide)-κ2N:O)barium(II), C4H10N8O6Ba
  56. Crystal structure of 2-amino-4-(3-phenoxyphenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C22H18N2O3
  57. Crystal structure of diethylammonium 5-((4-fluorophenyl)(6-hydroxy-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl)-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-olate, C23H30FN5O6
  58. Crystal structure of 2-amino-4-(3,5-difluoro-phenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C16H12F2N2O2
  59. Crystal structure of tris(N-nitroso-N-oxyanilino-κ2O, O′) oxidoniobium(V), C18H15N6O7Nb
  60. Crystal structure of 1-(5-benzoyl-4-methyl-2-(phenylamino)thiophen-3-yl)ethan-1-one, a structure with Z′ = 6, C20H17NO2S
  61. Crystal structure of diethyl-3-methyl-4-phenylthieno[2,3-b]thiophene-2,5-dicarboxylate, C19H18O4S2
  62. Crystal structure of 3,5-dicarboxybenzoate — benzene-1,3,5-tricarboxylic acid (1/1), C24H22N2O12
  63. The crystal structure of 2-chloro-1,3-bis(2,4,6-trimethylphenyl)-4,4-dimethyl-1,3,2λ3,4-diazaphosphasiletidine
  64. Crystal structure of hexaquamanganese(II) bis(hexaborato-κ3O,O′,O′′)manganese(II) dihydrate, B12H28Mn2O34
  65. Crystal structure of 1-propyl-3-methylimidazolium pentaborate, [C7H13N2][B5O6(OH)4]
  66. Crystal structure of 13-(4-fluorophenyl)-11,13-dihydro-1H-benzo[h]indazolo[6,7-b] [1, 6]naphthyridin-12(6H)-one — dimethylformamide — water (1/2/1), C29H31FN6O4
  67. Crystal structure of 1-(2-chlorophenyl)-2-(2-nitrophenyl)ethan-1-ol, C14H12ClNO3
  68. Crystal structure of (Z)-2-((2-bromo-1-phenylvinyl)oxy)benzonitrile, C15H10BrNO
  69. Crystal structure of tetrachlorido(1E,1′E)-N,N′-((1,4-phenylenebis(propane-2,2-diyl))bis(4,1-phenylene))bis(1-(pyridin-2-yl-κN)methanimine-κN)dizinc(II), C36H34N4Zn2Cl4
  70. Crystal structure of 2,6-bis(3-methylpyridinyl)hexahydro-4,8-ethenopyrrolo-[3,4-f]isoindole-1,3,5,7(2H,6H)-tetrone, C24H20N4O4
  71. Crystal structure of trans-bis(2-methylmaleato-κ2O,O′) bis(piperazinium-κN) cobalt(II) trihydrate, C18H36CoN4O11
  72. Crystal structure of (E)-4-chloro-N′-(4-(diethylamino)benzylidene)benzohydrazide, C18H20ClN3O
  73. Crystal structure of 3,6-di(1H-imidazol-1-yl)-9H-carbazole, C18H13N5
  74. Crystal structure of 4-(4-pyridinyl)-1-naphthoic acid, C16H11NO2
  75. Crystal structure of 1,1′-diformyl-4,4′-(6H,12H-5,11-methano-dibenzo[b,f][11,5]diazocine-2,8-diyl)dibenzene, C29H22N2O2
  76. Crystal structure of N′-(adamantan-2-ylidene)pyridine-3-carbohydrazide, C16H19N3O
  77. Crystal structure of 1,1′-(butane-1,4-diyl)bis(5-methyl-1H-pyrazole-3-carbaldehyde), C14H18N4O2
  78. Crystal structure of methyl 8-hydroxy-3-isopropyl-5a,8-dimethyl-2,3,4,5,5a,6,7,8,10a,10b-decahydrocyclohepta[e]indene-3a(1H)-carboxylate, C21H34O3
  79. Crystal structure of 6-oxo-4-propyl-2-(propylthio)-1,6-dihydropyrimidine-5-carbonitrile, C11H15N3OS
  80. Crystal structure of poly[diacetato(μ2-1,4-bis(1H-imidazol-1-yl)benzene-κ2N:N′)nickel(II)], C26H22N8NiO4
  81. Crystal structure of bis(2,4-dibromo-6-{(E)[(4-fluorobenzyl)imino]methyl}phenolato-κ2N,O) copper(II), C28H18Br4F2N2O2Cu
  82. Crystal structure of 1-(adamantan-1-yl)-3-phenylthiourea, C17H22N2S
  83. Crystal structure of 3-(6-(5-amino-1-phenyl-1H-pyrazol-3-yl)pyridin-2-yl)-1-phenyl-1H-pyrazol-5-amine – dioxan (2/1), C25H23N7O
  84. Crystal structure of 5-ethyl-6-[(3-methylphenyl)sulfanyl]pyrimidine-2,4(1H,3H)-dione, C13H14N2O2S
  85. Crystal structure of (((1E,1′E)-(cyclohexane-1,2-diylbis(azanylylidene-κ2N,N′))bis(methanylylidene))bis(2,1-phenylene))bis((2,6-diisopropylphenyl)amide-κ2N′′,N′′′)manganese(II), C44H54N4Mn
  86. Crystal structure of prop-2-en-1-yl 2-oxo-2H-1-benzopyran-3-carboxylate, C13H10O4
  87. Crystal structure of bis(μ2-2-((3-methylphenyl)imino)methylphenolato-κ2N,O:O)hexacarbonyldimanganese(I), C34H24Mn2N2O8
  88. Crystal structure of (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-hydroxybut-2-en-1-one C9H12N2O2
  89. Crystal structure of 2,2′-[pentane-1,5-diylbis(oxy)]dibenzaldehyde, C19H20O4
  90. Crystal structure of 2-phenyl-5,6,7,8-tetrahydro-4H-benzo[4,5]thieno[2,3-d][1,3]oxazin-4-one, C16H13NO2S
  91. Crystal structure of (E)-1-(2-chlorophenyl)-N-(4-chlorophenyl)methanimine, C13H9Cl2N
  92. Crystal structure of ethyl 2-amino-5-bromothiazole-4-carboxylate, C6H7BrN2O2S
  93. Crystal structure of 2-benzylisothiouronium tetraphenylborate, C32H31BN2S
  94. Crystal structure of poly[(μ2-biphenyl-2,2′-dicarboxylato-κ4O,O′:O′′,O′′′)(μ2-4,4′-bipyridine-κ2N:N′)copper(II)], C24H16CuN2O4
  95. Crystal structure of (η5-pentamethylcyclopentadienyl)titanium(III)dichloride (THF), C14H23Cl2OTi
  96. Crystal structure of 3-ferrocenylsulfonyl-2-(4-methoxyphenyl)-3H-imidazo[4,5-b]pyridine, C23H19FeN3O3S
  97. Crystal structure of 2-benzoyl-3-(4-fluorophenyl)cyclopropane-1,1-dicarbonitrile, C18H11FN2O
  98. Crystal structure of 1,6-ditosyl-1,6-diazecane, C22H30N2O4S2
  99. Crystal structure of N-phenyl-2-(pyridin-4-ylcarbonyl)hydrazinecarboxamide with Z′ = 4, C13H12N4O2
  100. Crystal structure of N,N-bis(diphenylphosphanyl)cyclohexylamine, C30H31NP2
  101. Crystal structure of 3-(4-hydroxy-3-methoxyphenyl)-N-phenylpropanamide, C16H17NO3
  102. Crystal structure of 6-(2-fluorophenyl)-3-phenyl-[1,2,4]-triazolo[3,4-b][1,3,4]thiadiazole, C15H9FN4S
  103. Crystal structure of catena-poly[aqua(dicyanoazanido-2κN-μ2-dicyanoazanido-1κN:2κN′)(μ2-2-methoxy-6-(((2-((3-methoxy-2-oxidobenzylidene)amino)ethyl)imino)methyl)phenolato-1κ2N,N′,2κ2O,O′,1κ2O′′,O′′′:2κ2O′′,O′′′)cadmium(II)copper(II)], C22H20CdCuN8O5
Heruntergeladen am 21.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2015-0212/html
Button zum nach oben scrollen